Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several safety/vaccination and contraindication claims align with the provided label excerpts, but two claims about live vaccine timing are not supported (the label states to complete age-appropriate vaccinations prior to initiation and to avoid live vaccines in patients treated with COSENTYX, without specifying 2-week before/after windows). Additional monitoring claims are partly aligned but lack explicit support for the specific conditions mentioned (major surgery/trauma).
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication that blocks the action of interleukin-17A (IL-17A).
Label excerpt includes active ingredient description and pharmacology context (IL-17A antagonist; COSENTYX is an IL-17 inhibitor).
Live vaccines should not be given to individuals with weakened immune systems, including those taking immunosuppressive medications such as biologics like Cosentyx.
Section 5.7: COSENTYX may alter immune response to live vaccines; avoid use of live vaccines in patients treated with COSENTYX.
Novartis recommends that patients receive live vaccines at least 2 weeks before starting Cosentyx.
Not explicitly supported by the provided excerpts; only supported generally as vaccinations should be completed prior to initiation (Section 2.1).
Novartis recommends that patients receive live vaccines at least 2 weeks after stopping Cosentyx.
Not explicitly supported by the provided excerpts; label states avoid live vaccines in patients treated with COSENTYX (Section 5.7) but does not specify post-discontinuation timing.
Cosentyx is contraindicated in patients with a history of hypersensitivity to secukinumab or any of the excipients.
Section 4: contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or any excipients.
Patients with a history of inflammatory bowel disease (IBD) should be closely monitored while taking Cosentyx.
Section 5.4: exercise caution when prescribing to patients with IBD and monitor for signs/symptoms.
Unsupported Statements
Novartis recommends that patients receive live vaccines at least 2 weeks before starting Cosentyx.
The provided label excerpts state to complete all age-appropriate vaccinations prior to initiating COSENTYX (Section 2.1) and to avoid live vaccines in patients treated with COSENTYX (Section 5.7), but do not specify a 2-week timing interval.
Novartis recommends that patients receive live vaccines at least 2 weeks after stopping Cosentyx.
The provided label excerpts do not specify any post-cessation interval for live vaccines; they only indicate avoidance of live vaccines in patients treated with COSENTYX (Section 5.7).
Patients with a history of major surgery or trauma should be closely monitored while taking Cosentyx.
No supplied label excerpt supports monitoring specifically for history of major surgery or trauma.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Boxed warnings status for COSENTYX was not addressed in the claims provided, but it is not possible to evaluate because the label excerpts supplied do not include boxed warning content.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The vaccination timing claims include specific 2-week before/after intervals not supported by the provided labeling excerpts, which could lead to incorrect scheduling assumptions. The surgery/trauma monitoring claim is unsupported by the provided label and may cause distraction or improper emphasis. Other claims (contraindication and IBD monitoring) are consistent with the excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Live vaccine timing claims ("at least 2 weeks before" and "at least 2 weeks after") and monitoring for major surgery/trauma are not explicitly supported by the supplied label excerpts.
Suggested Improvement
Replace the 2-week before/after statements with label-supported language: complete all age-appropriate vaccinations prior to initiating COSENTYX (Section 2.1) and avoid use of live vaccines in patients treated with COSENTYX (Section 5.7). Remove or rephrase the major surgery/trauma monitoring claim unless supported by additional label text not provided.